Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: NAT10 as a potential prognostic biomarker and therapeutic target for HNSCC

Fig. 5

Both genetic and pharmacologic inhibition of NAT10 suppressed the migration and invasion in human HNSCC cells. a–f A cell scratch assay was performed, and three cell lines were treated with either Remodelin or siRNA. Representative figures are shown. ImageJ was used to calculate the area without cells, and the results indicated that the cell migration abilities were decreased after NAT10 was inhibited. g For the migration assay, cell lines were treated with siRNA targeting NAT10 or Remodelin and approximately 105 cells were seeded in the apical chamber of the Transwell. Crystal violet staining was performed 48 h later. The migration ability of the three cell lines was decreased as shown. For the invasion assay, the apical chamber of the Transwell was precoated with Matrigel. Cell lines were treated with siRNA targeting NAT10 or Remodelin, and approximately 105 cells were seeded in the apical chamber of the Transwell. Crystal violet staining indicated decreased invasion ability of the three cell lines after NAT10 was inhibited. A t test was used to compare two groups for statistical analysis, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page